Published online Jun 30, 2007.
https://doi.org/10.4111/kju.2007.48.6.574
Continuing Trends of the Clinical Parameter Migration in Patients with Prostate Cancer in Korea
Abstract
Purpose
With the widespread use of screening for prostate-specific antigen (PSA), T1c prostate cancer has shown a marked increase in Western countries. We reviewed the trends in clinical stage migration and the changes in the clinical characteristics for patients with prostate cancer in Korea, and we compared these values with those of Western men.
Materials and Methods
Between 1997 and 2006, 758 men (mean age: 68.6 years) were diagnosed with prostate cancer at our institution. According to the diagnostic period, the patients were divided into 3 groups (the 1997-2000, 2001-2003 and 2004-2006 groups) for comparative analysis of the clinical stage, the serum PSA level and the biopsy Gleason score.
Results
The proportion of clinically localized prostate cancer significantly increased by the period (56.8%, 62.5% and 75.4%, respectively; p<0.001) with that of metastatic disease showing a decreasing according to groups (40.0%, 27.5% and 17.6%, respectively; p<0.001). For localized disease, T1c cancers also increased from 26.4% to 19.2% to 31.6% (p=0.002), respectively. The median serum PSA level at diagnosis decreased from 34.5 ng/ml to 16.6ng/ml to 10.8ng/ml (p<0.001), respectively, with the proportion of patients with a PSA level≤10ng/ml increasing significantly (19.2%, 33.3% and 47.7%, respectively; p<0.001). Although the proportion of biopsy Gleason scores that were 8-10 decreased from 71.2% to 50.2% to 38.3%, respectively, it still comprised 20.8% of the T1c cancers and 22.8% of the cancers with a PSA≤10ng/ml in the last period, and these values were significantly higher than those in the Western reports.
Conclusions
Downward migration of the clinical stage along with decreases for the serum PSA level and biopsy Gleason score were evident in Korean men. However, the proportion of T1c cancer was still lower than that in the Western series and the fraction of Gleason score 8-10 cancer was distinctively high. We believe this mandates establishing PSA screening programs and administering vigorous management.
Fig. 1
The clinical stage according to diagnostic period.
Fig. 2
Correlation between serum the prostate-specific antigen (PSA) level and the prostate biopsy Gleason score.
Table 1
The clinical and histological changes according to the diagnostic period
Table 2
The clinical and histological changes of clinically localized prostate cancer
References
-
Cancer Registration and Biostatistics Branch, National Cancer Center. Cancer Statistics in Korea. 2003.
-
-
Murphy GP, Natarajan N, Pontes JE, Schmitz RL, Smart CR, Schmidt JD, et al. The national survey of prostate cancer in the United States by the American College of Surgeons. J Urol 1982;127:928–934.
-
-
Kim SD, Sung GT, Yoon JH. Epidemiological survey of prostate cancer prevalence in Kangseo-gu, Busan, Korea. Korean J Urol 2003;44:1251–1255.
-
-
Nakata S, Ohtake N, Kubota Y, Ito K, Suzuki K, Yamanaka H, et al. Chronological changes of incidence rates, clinical stages and pathological differentiation of prostate cancer in Gunma Prefecture, Japan. Hinyokika Kiyo 2004;50:165–170.
-